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Seroepidemiology, pathology, and animal studies provide evidence for a possible association
between Chlamydia pneumoniae infections and atherosclerosis, coronary heart disease, and
myocardial infarction. If this association exists, then exposure to certain antibiotics may
positively affect the clinical course after an acute ischemic cardiac event (secondary prevention)
and affect the risk of developing a first-time myocardial infarction (primary prevention).
Preliminary evidence from clinical trials suggests that treatment with new macrolide antibiotics
may improve outcome after ischemic events, and evidence from a large case-control analysis
indicates that exposure to tetracyclines or quinolones may reduce the risk of developing a
first-time myocardial infarction. However, antibiotics for the treatment or prevention of ische-
mic heart disease must not be recommended yet. This review of published studies briefly
summarizes the currently available literature on the effects of antibiotics on the risk of de-
veloping coronary heart disease and myocardial infarction.
The well-documented risk factors for atherosclerosis, coro-
nary heart disease (CHD), and myocardial infarction (MI) (e.g.
hyperlipidemia, hypertension, obesity, lack of physical exercise,
smoking) do not sufficiently account for all new cases of MI.
Thus, the search for additional risk factors that may play a
role in the etiology of atherosclerosis and ischemic heart disease
is important since ischemic heart disease is a major cause for
morbidity and mortality in industrialized countries [1, 2].
Chlamydia pneumoniae was first detected in the 1960s, and
∼15 years ago it was isolated from respiratory tissue and iden-
tified as a respiratory pathogen [3, 4]. The first report about a
high prevalence of elevated antibody titers against this bacte-
rium in subjects with MI [5] raised speculations about a possible
causal involvement of C. pneumoniae infections in the etiology
of atherosclerosis, CHD, and MI. The majority of a large num-
ber of seroepidemiology studies [6–13] added evidence to the
increasing body of literature suggesting a possible relationship
of C. pneumoniae infections to the pathophysiology of ather-
osclerosis and subsequent ischemic heart disease. This associ-
ation, however, was not found in all studies: Three US-based
analyses failed to show an association between serum antibody
(IgG) and subsequent cardiac events [14–16]. In these studies,
baseline IgG titers for subjects who developed CHD during
follow-up were compared with those for control subjects. In
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contrast, research on human pathology samples [17–26] and
animal models [27–30] provided further evidence that infections
with C. pneumoniae may play a role in the etiology of ather-
osclerosis and ischemic heart disease.
In a public health context, a risk factor for a disease needs
to be sufficiently strong and prevalent to substantially contrib-
ute to the etiology of a disease. C. pneumoniae has been shown
to be frequently involved in respiratory tract infections in all
age groups, with its most likely mode of spread being respi-
ratory secretions [31–35]. In industrialized countries, the prev-
alence of elevated antibody titers against C. pneumoniae as a
marker for previous infections with this agent is between
50%–70% in a middle-aged population [33, 36]. Many subjects
acquire a first infection in childhood, and reinfections with C.
pneumoniae during adult life are common [33]. The presence of
C. pneumoniae in subjectively healthy, asymptomatic subjects
is not uncommon [37, 38]. Respiratory infections with C. pneu-
moniae are commonly characterized by a mild, self-limiting clin-
ical course [36, 39], which often does not warrant medical at-
tention. The main symptoms of such chest infections are mild
fever, hoarseness, and cough. Due to their mild clinical course,
it can be assumed that many respiratory tract infections with
C. pneumoniae are not treated with antibiotics and that such
infections could, therefore, become chronic.
The Possible Role of Antibiotics for CHD and MI
If a causal association between bacterial infections with C.
pneumoniae and the risk of developing CHD and MI indeed
exists, one would expect that exposure to certain antibiotics
may reduce the risk of developing ischemic cardiovascular dis-
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eases. The treatment of choice for the eradication of C. pneu-
moniae is not well established. In vitro studies have been done
to assess inhibitory concentrations for the elimination of bac-
teria, but information from in vivo studies in humans is scarce.
Information from in vivo studies would be important because
pharmacokinetic properties of antibiotics (i.e., the capability of
penetrating infected tissue) play an important role in success-
fully treating infections in vivo.
On the basis of available information, tetracycline antibiot-
ics (tetracycline, oxytetracycline, minocycline) are efficacious
against C. pneumoniae. Furthermore, new macrolides (azith-
romycin, roxithromycin, clarithromycin) are also highly active,
while erythromycin is of uncertain efficacy against C. pneu-
moniae unless used in high doses for at least 2 weeks [40–45].
The new quinolones (e.g., grepafloxacin) are also highly effi-
cacious against C. pneumoniae in vitro, but data on larger pa-
tient series are lacking. The in vitro inhibitory minimal con-
centrations of older quinolones (ciprofloxacin, norfloxacin)
suggest some antibacterial activity in vivo. Sulfonamides and
b-lactam antibiotics (penicillins, cephalosporins) are considered
not to be efficacious against C. pneumoniae [40–45]. It must,
however, be emphasized again that a comparison of the relative
effectiveness of various antibiotics is difficult because efficacy
in vitro does not necessarily reflect clinical efficacy in vivo.
Treatment of CHD and MI with Antibiotics
Much attention has been paid to two clinical trials that stud-
ied the effect of newer macrolide antibiotics on the short-term
outcome after an acute cardiac event [46, 47]. A comparison
of these studies is limited by the fact that one focused entirely
on subjects with increased titers against C. pneumoniae anti-
bodies, while the other included subjects who did not have
elevated antibody titers against C. pneumoniae. Furthermore,
treatment with antibiotics started early after an ischemic event
in one study [46] but at various points in time after an MI in
the other [47]. Both studies were rather small ( and 202,n = 220
respectively) and yielded results that have to be viewed as in-
triguing but preliminary.
Gurfinkel et al. [46] treated patients who had unstable angina
pectoris or non–Q-wave MI with placebo or with roxithromycin
(150 mg orally) twice a day for 30 days and analyzed the data
after 1 month [46] and 90 and 180 days [48]. The primary
clinical end points were cardiac ischemic death, MI, or severe
recurrent ischemia during follow-up. The authors reported a
statistically significant difference between the treatment and the
placebo group after 30 days of follow-up: In the placebo group,
there were 9 subjects with a triple end point (i.e., severe recur-
rent angina, plus acute MI, plus ischemic death), and in the
roxithromycin group, there was only 1 subject with a triple end
point ( ) [46]. Of interest, this difference was weakerP = .036
after 90 days (12 subjects in the placebo group and 3 in the
roxithromycin group had triple end points, ) and non-P = .058
significant after 180 days (14 subjects in the placebo group and
7 in the roxithromycin group had triple end points, )P = .334
[48].
Gupta et al. [47] reported the findings of a clinical trial in
which they included male subjects who attended a post-MI
outpatient clinic. MI survivors were stratified into three groups
according to their level of IgG antibodies; subjects with the
highest antibody titers (>1/64) were treated either with placebo
or with azithromycin (500 mg/day) for 3 or 6 days. There was
also a significant difference between the treatment and the pla-
cebo groups in the number of recurrent adverse cardiac events
after a mean follow-up of 18 months. Subjects in the placebo
group who had the highest antibody titers against C. pneu-
moniae had an ∼4-fold increased risk of developing recurrent
cardiac ischemia, compared with subjects with no increased
antibody titers against C. pneumoniae. Subjects in the highest
antibody titer group who received treatment with azithromycin
did not have an elevated risk of developing recurrent ischemia,
compared with subjects with no evidence of increased antibody
titers against C. pneumoniae (odds ratio [OR], 0.9; 95% con-
fidence interval [95% CI], 0.2–4.6) [47].
Anderson et al. [49] randomized subjects with elevated an-
tibody titers and CHD to receive either placebo or a 3-month
course of azithromycin. There was no difference with regard to
the clinical outcome (adverse ischemic cardiac events), but the
treatment group had significantly lower inflammation markers
(e.g. interleukin-6, C-reactive protein) than the placebo group
[49].
These secondary prevention trials suggest that the newer ma-
crolide antibiotics, azithromycin and roxithromycin, have some
effect on inflammation markers or clinical outcome (or on both)
after an acute ischemic cardiac event; however, these findings
do not yet allow the inference that there is a causal involvement
of C. pneumoniae in the outcome and the survival rate of CHD
patients. The observed results suggest some effect of these ma-
crolide antibiotics, but it is not clear whether this has to do
with eradication of C. pneumoniae or with some other phar-
macologic nonantibiotic effects of macrolides. Indeed, the re-
sults reported by Anderson et al. [49] and the final analysis of
Gurfinkel et al. [48] provide evidence that the beneficial effects
of macrolides may be of rather short duration and based on
acute anti-inflammatory effects of these compounds rather than
on antibiotic properties.
Some antibiotics, such as tetracyclines or macrolides, have
been shown to have pharmacologic effects beyond antibacterial
efficacy, such as antioxydative effects and inhibitory effects on
metalloproteinases [50–52], which in turn have been shown to
be involved in plaque instability and rupture. Thus, inhibition
of metalloproteinases may lead to stabilization of previously
unstable atherosclerotic plaque and to an improvement of the
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clinical outcome of patients with unstable CHD independently
of any antibacterial efficacy of these antibiotics [50–55].
Prevention of First-Time Acute MI with Antibiotics
While these randomized clinical trials [46, 47, 49] have been
conducted in patients with ischemic heart disease (i.e., second-
ary prevention of CHD), the effect of antibiotic exposure on
the risk of developing a first-time cardiac ischemic event (i.e.,
primary prevention) has also been explored. While such a ques-
tion would be extremely difficult to study prospectively because
of the large number of subjects needed and the high costs in-
volved, it was possible to study the effect of antibiotic exposure
in large retrospective case-control analyses [56, 57]. These two
epidemiology studies were based on two hypotheses: (1) infec-
tions with bacteria (e.g., C. pneumoniae) involved in the etiology
of CHD are highly prevalent, the clinical course of such an
infection is often mild, and appropriate eradication is rarely
done in the general population; and (2) exposure to certain
antibiotics may alter the risk of developing an acute MI, re-
gardless of the indication for the antibiotic.
Meier et al. [56] analyzed the patient records and the exposure
history to certain antibiotics of 3315 cases with an acute, first-
time MI and of 13,139 control subjects who were matched to
cases by age, sex, calendar year, and general physician’s practice
attended. The database used was the large and well-documented
UK-based General Practice Research Database [58–60]. The
study was restricted to subjects who were free of any docu-
mented clinical risk factors (e.g., angina pectoris, hypertension,
hyperlipidemia, clotting disorders, diabetes mellitus) prior to
the MI. For each study subject, antibiotic exposure in the 3
years prior to the date of the MI (or the corresponding date
in the matched controls) was assessed from the computerized
record and categorized as follows: users of tetracyclines only,
macrolides only, quinolones only, sulfonamides only, penicillins
only, cephalosporins only, or mixed exposure (i.e., subjects who
received prescriptions for various antibiotics across categories).
The results of the multivariate conditional logistic regression
analysis, adjusted for smoking status and body mass index,
yielded a significant difference between the proportion of con-
trols and MI cases using tetracyclines (OR, 0.70; 95% CI,
0.55–0.90) or quinolones (OR, 0.45; 95% CI, 0.21–0.95) in the
3 years preceding the event date. No such effect was found for
macrolides (predominantly erythromycin use; OR, 0.93; 95%
CI, 0.73–1.20), sulfonamides (OR, 1.01; 95% CI, 0.79–1.29),
penicillins (OR, 0.94; 95% CI, 0.85–1.04), or cephalosporins
(OR, 0.90; 95% CI, 0.67–1.22) [54]. Further stratification of
exposure by daily tetracycline dose yielded an OR of 0.71 (95%
CI, 0.55–0.91) for users of a regular dose and of 0.67 (95% CI,
0.30–1.53) for users of a high dose. Compared with non-use of
antibiotics, use of one to two prescriptions for a macrolide
antibiotic in the 3 years preceding the date of the MI (or the
corresponding date in matched controls) resulted in an OR of
1.03 (95% CI, 0.79–1.36), and use of three or more prescriptions
resulted in an OR of 0.61 (95% CI, 0.34–1.11) [56].
In a similar retrospective case-control analysis using data
from a large health maintenance organization (Group Health
Cooperative of Puget Sound, Seattle), Jackson et al. [57] an-
alyzed the records of 1796 cases with an incident MI and 4882
matched controls. They did not find any evidence for a pro-
tective effect of previous use of tetracyclines or erythromycin
in the primary prevention of MI. Stratification by cumulative
duration of treatment did not suggest a reduced risk of devel-
oping an MI in association with increasing treatment duration
(1–14, 15–28, 291 days). No stratified analysis according to
daily dose of antibiotic use was presented; this may have added
relevant information because a short treatment with a high
daily dose may be more effective in treating a particular infec-
tion than a longer-term, low-dose treatment.
One possible explanation for the lack of effect observed by
Jackson et al. [57] may be the fact that they included MI cases
with a history of cardiovascular risk factors for MI (e.g., 26%
of the case patients had angina pectoris, 75% had hypertension,
and 27% had diabetes mellitus), while Meier et al. [56] included
only previously healthy subjects (both cases and controls) who
did not have cardiovascular or metabolic diseases predisposing
for MI. The elimination of subjects with preexisting risk factors
allows for better detection of an isolated risk factor of interest,
while it is extremely difficult to measure the effect of a single
newly hypothesized risk factor of interest in a population that
already has numerous clinical diseases that predispose to de-
velopment of the outcome of interest [61].
However, the intriguing findings of Meier et al. [56] also need
careful interpretation for various reasons even though they may
fit well in the hypothesis that bacteria susceptible to tetracy-
clines or quinolones are involved in the etiology of acute MI
(e.g., C. pneumoniae). The observed effect (a reduced risk of
developing a first-time MI after exposure to tetracyclines or
quinolones) may indeed reflect a real finding and could be due
to eradication of C. pneumoniae from the organism or, as dis-
cussed above, due to some other pharmacologic mechanisms,
such as the anti-inflammatory effect of tetracyclines [50–55].
Alternative explanations, however, may be chance or residual
confounding of poorly measurable parameters, such as socio-
economic status. The term “confounding” describes a spurious
association between exposure and outcome due to the presence
of a third factor, which is related both to the exposure and the
outcome. Socioeconomic status is a multifactorial and poorly
defined potential confounder, and it has been postulated that
the observed association between infections and CHD may be
explained, at least in part, by confounding by socioeconomic
status; thus, subjects with low socioeconomic status have in-
dependently both a higher likelihood of acquiring respiratory
tract infections (e.g., through household crowding) and of de-
veloping CHD (e.g., through low-quality, fat-rich diet, or other
risk factors). In the analysis of Meier et al. [56], such con-
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founding would have had to selectively affect exposure to tet-
racyclines or quinolones but not of other antibiotics; this sug-
gestion seems unlikely but cannot be excluded entirely.
A major limitation of both the case-control analyses of Meier
et al. [56] and Jackson et al. [57] is the fact that no information
was available on seroepidemiologic parameters for cases and
controls. Thus, the study population is a heterogeneous mixture
of subjects with or without previous exposure to C. pneumoniae;
in addition, subjects with previous infections to C. pneumoniae
may substantially differ with regard to the number, severity,
and timing of previous infections with C. pneumoniae. Fur-
thermore, subjects may have been seropositive but acquired the
infection after antibiotic exposure, while other subjects may
indeed have had a C. pneumoniae infection prior to use of an
antibiotic. It would have been of major interest, but unfortu-
nately not feasible, to include only cases and controls with
known antibody titers and a known temporal sequence of in-
fection followed by antibiotic exposure; a subanalysis of these
subjects—if possible—might have further clarified the issue. In
addition, for many exposed subjects the magnitude of antibiotic
use may have been too small for an effect on the outcome
because antibiotics have been prescribed for various indications
(other than respiratory tract infections with C. pneumoniae) not
requiring longer-term or high-dose treatment.
Conclusion
Two randomized placebo-controlled trials [46, 47] of the sec-
ondary prevention of MI and a large retrospective case-control
analysis exploring the effect of antibiotic exposure as primary
prevention of MI [56] yielded intriguing evidence that certain
antibiotics may have an effect on atherosclerosis, CHD, and
MI. However, additional large-scale clinical trials are needed
to collect data on whether certain antibiotics indeed alter the
course of ischemic heart disease, as indicated in these prelim-
inary findings. Such controlled trials need to be large in size
and well-targeted to particular subgroups of interest, such as
subjects with elevated antibody titers who are otherwise free of
major risk factors for CHD. Until there is a better understand-
ing of the molecular mechanisms of infection-induced athero-
sclerosis and more direct evidence for a causal pathway, use of
antibiotics in the prevention or treatment of CHD is premature
and must not be recommended outside well-controlled trials.
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